A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, albeit with a high incidence of hematologic toxicity and infections. The ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...
Results for talquetamab presented at the 64th American Society of Hematology Annual Meeting and Exposition showed that about 70% of patients with multiple myeloma had responses. More than 70% of ...
Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.
Please provide your email address to receive an email when new articles are posted on . Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory ...
“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Patients with newly diagnosed multiple myeloma treated with the four-drug combination of Sarclisa (isatuximab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback